Juneau, Paul

A phase I/IItrial of MYO‐029 in adult subjects with muscular dystrophy

Wagner, K. R., Fleckenstein, J. L., Amato, A. A., Barohn, R. J., Bushby, K., Escolar, D. M., Flanigan, K. M., Pestronk, A., Tawil, R., Wolfe, G. I., et al. (2008) · Annals of Neurology

Muscle Physiology and DisordersNeurogenetic and Muscular Disorders Research

Cited by 481

Transferrin and Iron in Normal, Alzheimer's Disease, and Parkinson's Disease Brain Regions

Loeffler, D. A., Connor, J. R., Juneau, P. L., Snyder, B. S., Kanaley, L., DeMaggio, A. J., Nguyen, H., Brickman, C. M., & LeWitt, P. A. (1995) · Journal of Neurochemistry

Iron Metabolism and DisordersNeurological diseases and metabolism

Cited by 334

Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon‐like peptide‐1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once‐weekly exenatide and liraglutide

Alatorre, C., Fernández Landó, L., Yu, M., Brown, K., Montejano, L., Juneau, P., Mody, R., & Swindle, R. (2017) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementMedication Adherence and Compliance

Cited by 111